Onco360 has been chosen as a trusted specialty pharmacy to dispense VONJO™ - the first FDA approved therapy that specifically addresses the needs of Adult Cytopenic Myelofibrosis.
BESREMi® (ropeginterferon alfa-2b-njft) Now Approved for the Treatment of Adults with Polycythemia Vera
EXKIVITY (mobocertinib) approved and Takeda has selected Onco360® as a Specialty Pharmacy Partner
Onco360® has been selected by Merck & Co., Inc. to be in the specialty pharmacy network for WELIREG (belzutifan) ), a hypoxia-inducible factor inhibitor indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
REZUROCKTM (belumosudil) tablets approved to treat adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least two prior lines of therapy
LUMAKRAS (Sotorasib) Now Approved for the Treatment of Adult Patients with KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
ALUNBRIG® (brigatinib) Approved for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)-positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Onco360® Selected as Specialty Pharmacy Partner for FOTIVDA® (tivozanib)
UKONIQ™ (umbralisib) Now Approved by the FDA; Onco360® Selected as Exclusive Specialty Pharmacy Partner
Onco360® to provide 50,000 meals to children and families through Feeding America's network of food banks.
TAZVERIK™ (tazemetostat) is now approved for the treatment of relapsed/refractory follicular lymphoma, available from Onco360.
Onco360® has been selected by Eli Lilly to be a specialty pharmacy partner for RETEVMO™ (selpercatinib), a novel oral treatment for adult patients with (RET) fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and metastatic RET fusion-positive thyroid cancer.
Onco360®, has been selected by Seattle Genetics to be a specialty pharmacy partner for TUKYSA™ (tucatinib), a new oral treatment used in combination with capecitabine and trastuzumab for adult patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Onco360® has been selected by AstraZeneca to be a specialty pharmacy partner for KOSELUGO® (selumetinib), a novel oral kinase inhibitor indicated for the treatment of pediatric patients aged two years and above, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas.
In response to the current COVID-19 situation, we’ve examined all areas of our business and pharmacy operations at every Onco360 location across the country and have taken actions to ensure continued service to our patients and their caregivers.
Onco360 is aware of the emergence of the new coronavirus (COVID-19) illness and is closely monitoring the situation and possible future impact.
Onco360 has been selected by Epizyme to be the specialty pharmacy partner for TAZVERIK™ (tazemetostat), a new oral treatment for adult and pediatric patients (aged 16 years and older) with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
ENHERTU® now available from Onco360.
BRUKINSA™ Now Available from Onco360
Onco360 is privileged to be selected as a specialty pharmacy provider for INREBIC®.
NUBEQA® is available now through Onco360 Oncology Specialty Pharmacy.
The impact of the budding hurricane, Tropical Storm Barry, on the Gulf of Mexico region is expected to be significant and may affect our pharmacy operations and delivery in limited areas.
Onco360 is selected as 1 of 3 specialty pharmacies to dispense XPOVIO™ (selinexor).
The National Association of Specialty Pharmacy (NASP) has announced a scholarship program created in memory of our friend and colleague, Ron Bookman.
It is with great sadness that we announce the passing of our friend and colleague, Ron Bookman, on March 5, 2019.
Onco360 was selected as 1 of only 3 Specialty Pharmacy providers to dispense XOSPATA® (Gilteritinib) for the treatment of patients with relapsed or refractory FMS-like Tyrosine Kinase 3 (FLT3) mutation-positive acute myeloid leukemia (AML).
Talzenna® and Vizimpro® available now through Onco360 Oncology Specialty Pharmacy.
Onco360 Selected as the Exclusive Specialty Pharmacy for Libtayo® (cemiplimab-rwlc) Limited Distribution Pharmacy Network.
Onco360 selected to participate in the limited distribution network for Array Biopharma’s new products BRAFTOVI™ (encorafenib) and MEKTOVI® (binimetinib) for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test.
Now Available From Onco360 - The New IMBRUVICA® pill is now available as a one pill, once a day treatment.
Onco360 has been selected to participate in the limited distribution network for Eli Lilly's new product, VERZENIO (Abemaciclib)
Onco360 announces selection to highly limited pharmacy network for NERLYNX.
Onco360 announces selection to highly limited pharmacy network for VENCLEXTA.
Limited distribution medication XALKORI (crizotinib) receives approval for certain NSCLC patients.
Limited distribution breast cancer medication IBRANCE approved for additional indication.
Imatinib Mesylate (generic Gleevec) was recently approved for 7 indications.
Combination therapy receives accelerated approval for new indication. OPDIVO also receives additional indication as a single therapy.
Onco360 Selected for Lonsurf Limited Distribution Pharmacy Network
Onco360 Receives URAC Specialty Pharmacy Accreditation...
Newly Approved Ibrance® (palbociclib) From Pfizer Available Through Onco360; Company Again Selected as Limited Distribution Pharmacy Provider
Onco360 Chosen By Bayer As Limited Distribution Pharmacy Provider
Company’s Comprehensive Drug Portfolio Further Expands with Addition of Two Leading Products
Onco360 Selected by Pfizer as Limited Distribution Pharmacy Provider;
Expands Onco360’s Industry-Leading Portfolio to Nearly 40 Products
Onco360 Appoints Paul Jardina as President and Chief Executive Officer
Jardina Brings More Than 20 Years of Healthcare Industry Experience
Zydelig® (idelalisib) approved and available for order through Onco360